- Home
- ASAN vs ATAI Comparison
ASAN vs ATAI Comparison
Compare ASAN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | ATAI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ASAN | ATAI |
|---|---|---|
| Price | $7.88 | $4.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $12.46 | ★ $15.88 |
| AVG Volume (30 Days) | ★ 6.8M | 4.4M |
| Earning Date | 06-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $790,806,000.00 | $4,089,000.00 |
| Revenue This Year | $10.19 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.25 | ★ 1227.60 |
| 52 Week Low | $5.38 | $2.00 |
| 52 Week High | $15.71 | $6.73 |
Technical Indicators
Market Signals| Indicator | ASAN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 59.11 |
| Support Level | $7.15 | $3.44 |
| Resistance Level | $8.20 | $5.43 |
| Average True Range (ATR) | 0.51 | 0.26 |
| MACD | 0.22 | 0.06 |
| Stochastic Oscillator | 59.73 | 62.50 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.